Effect of atorvastatin on lipid and cardiovascular events in patients on maintenance hemodialysis


  • Muhammed Arshad Ul Azim Assistant Professor, Department of Nephrology, Shahid Sheikh Abu Naser Specialized Hospital, Khulna, Bangladesh
  • Md Habibur Rahman Professor, Department of Nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
  • Abdus Salam Assistant professor, Department of Neurology, Shahid Sheikh Abu Naser Specialized Hospital, Khulna, Bangladesh
  • Sayed Mahtabul Islam Assistant professor, Department of Nephrology, Chittagong Medical College, Chittagong, Bangladesh
  • Shahryar Waheed Assistant professor, Department of Nephrology, Sir Salimullah Medical College, Dhaka. Bangladesh




atorvastatin, cardiovascular events, hemodialysis, lipid profile


Background: Cardiovascular disease is the major cause of death in chronic kidney disease patient as well as in patients on hemodialysis. Dyslipidaemia is highly prevalent in patients on maintenance haemodialysis which increases the risk for cardiovascular mortality. This study was designed to evaluate the lipid abnormalities, effect of atorvastatin on lipid profile and cardiovascular events in patients on maintenance hemodialysis.

Methods: In this prospective clinical study, 55 end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis participated voluntarily. The study population was divided randomly into group-A (atorvastatin was prescribed) and group-B (without atorvastatin). We compared the lipid status and cardiovascular events of both groups after 6 months.

Results: The two groups of patients were well matched in respect to baseline characteristics, history of risk factors and dialysis duration and session. Mean age of study population was about 48 years. Low density lipoprotein (LDL) cholesterol was reduced by 18.79%, total cholesterol was reduced by 9.32% and triglyceride was reduced by 22% in group-A. In group-A, high density lipoprotein (HDL) cholesterol was increased by 6% and it was reduced by 6% in group-B. In this study, myocardial ischemia/infarction on electrocardiogram (ECG) was present 22% in group-A and 14% in group-B at randomization. After 6 months, ischemia/infarction was found 33% in group-A and 25% in group-B. Statistically the ECG findings showed no significant changes after 6 months. In this study, mean ejection fraction (EF %) was 54% in group-A and 51% in group-B at 0 month, after 6 months atorvastatin group failed to show any significant change. In this study, after 6 months of statin therapy there was slight increase of serum glutamic pyruvic transaminase (16.13%) but that was not significant.

Conclusion: In this study atorvastatin improved the lipid abnormalities significantly but a significant reduction of cardiovascular events was not achieved.

Birdem Med J 2020; 10(1): 34-39


Download data is not yet available.




How to Cite

Azim, M. A. U., Rahman, M. H., Salam, A., Islam, S. M., & Waheed, S. (2019). Effect of atorvastatin on lipid and cardiovascular events in patients on maintenance hemodialysis. BIRDEM Medical Journal, 10(1), 34–39. https://doi.org/10.3329/birdem.v10i1.44758



Original Articles